Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com Prev Post Completion of Tranche 1 of the Placement December 20, 2024 Next Post Navigating the Indecisive SPY: What Investors Should Know December 20, 2024 Related Posts When is the Starlink IPO Date and Can You Invest? January 22, 2025 Ioneer Closes US$996 Million American Government Loan for Rhyolite Ridge January 22, 2025 Cespira Appoints Carlos Gonzalez as President and CEO January 22, 2025